[Goose]

Sure, but we don't have monoclonal Abs yet, and there's some work to be done to determine the best agent as well.  Remember that the CP initiative started early March and was treating patients by beginning of April.  At that time it was compassionate care.  They need controlled studies but the track record of those pushing this Tx have a better track record than those pushing HCQ.

For sure agree. There are well accepted mechanisms of action associated with CP. In no way can it be considered similar to the HCQ conjectures.

I think it shows how well-designed clinical studies need to be started ASAP before end-arounds allow word of mouth to build with increasing reluctance to participate in those critical studies.

Also agree. These studies take time, so the sooner the better. The studies may also reveal things about CP therapies that allow it to be even more effective that it is at present.  It may be some populations benefit much more than others, or that some dose profile work better than others.

[Goose]

Sure, but we don't have monoclonal Abs yet, and there's some work to be done to determine the best agent as well.  Remember that the CP initiative started early March and was treating patients by beginning of April.  At that time it was compassionate care.  They need controlled studies but the track record of those pushing this Tx have a better track record than those pushing HCQ.

For sure agree. There are well accepted mechanisms of action associated with CP. In no way can it be considered similar to the HCQ conjectures.

I think it shows how well-designed clinical studies need to be started ASAP before end-arounds allow word of mouth to build with increasing reluctance to participate in those critical studies.

Also agree. These studies take time, so the sooner the better. The studies may also reveal things about CP therapies that allow it to be even more effective that it is at present.  It may be some populations benefit much more than others, or that some dose profile work better than others.